Researchers have developed an engineered feeder cell line, ARH-77, which significantly enhances the production of allogeneic natural killer (NK) cells, a promising avenue for adoptive cell therapy targeting cancer. Traditional production methods have struggled to yield NK cells in sufficient quantities for therapeutic use, with existing cell lines like K562 providing only modest expansion rates.
In a study led by Sang-Ki Kim, DVM, PhD, and Seung-Hwan Lee, PhD, the modified ARH-77 cell line achieved a remarkable 101,241-fold expansion of NK cells over 28 days, compared to just 155-fold from K562 cells. This advancement stems from the incorporation of four specific stimulatory ligands—B7-H6, CD137L, IL-15, and IL-15Rα—designed to enhance NK cell activation, proliferation, and persistence.
While the findings suggest ARH-77 could serve as a reliable platform for NK cell expansion, further research is necessary to validate the individual contributions of each ligand and assess the cell line’s efficacy in vivo. The stability of feeder cell performance across donor populations indicates potential for consistent and scalable NK cell manufacturing, which is crucial for the future of clinical adoptive immunotherapy.
Open the full market picture for your next decision →
